Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Handwriting patterns in isolated rapid eye movement sleep behaviour disorder.

Journal of Parkinson's disease·2026
Same author

Beyond Pathology: α-Synuclein Homeostasis and Three Principles to Guide Research.

Movement disorders clinical practice·2025
Same author

'Pathology is disease' Parkinson's mythology: The 'brain-first-body-first' case study.

Journal of Parkinson's disease·2025
Same author

Licensed Subcutaneous Infusion Therapies in Advanced Parkinson's Disease: An Indirect Treatment Comparison and Cost-Minimisation Analysis.

Neurology and therapy·2025
Same author

Refutation of the αSyn-SAA-Based Staging for Parkinson's Progression (Neuronal α-Synuclein Disease-Integrated Staging System [NSD-ISS]).

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

The resurrection of apomorphine: A dopamine analogue comparable in potency to L-DOPA.

Parkinsonism & related disorders·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Jun 22, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

パーキンソン病 パーキンソン病

Andrew J Lees1, John Hardy, Tamas Revesz

  • 1Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London and the National Hospital for Neurology and Neurosurgery, London, UK. alees@ion.ucl.ac.uk

Lancet (London, England)
|June 16, 2009
PubMed
まとめ
この要約は機械生成です。

パーキンソン病は一般的な神経変性疾患で,脳細胞の喪失とアルファ-シナヌクレインの蓄積が伴う. 治療は運動症状を管理し,生活の質を改善し,幹細胞と遺伝子療法は将来の希望を示しています.

さらに関連する動画

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

関連する実験動画

Last Updated: Jun 22, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

科学分野:

  • 神経学 神経学とは
  • 神経科学は神経科学である.
  • 遺伝学 遺伝学とは

背景:

  • パーキンソン病は進行性ブロディキネティック障害である.
  • 主な病理学的特徴には,ニグラ細胞の喪失とアルファ-シヌクレインの集積が含まれます.
  • 年齢は主な危険因子であり,遺伝的傾向も重要な役割を果たしています.

研究 の 目的:

  • パーキンソン病の主要な特徴,危険因子,治療方法についてまとめます.
  • 診断の正確性と病理学的根拠を強調する.
  • 現在のおよび新興の治療戦略について議論する.

主な方法:

  • パーキンソン病の病理学と臨床プレゼンテーションに関する既存の文献のレビュー.
  • 病気の感受性に寄与する遺伝的要因の分析.
  • 現在の治療介入と将来の研究方向の評価.

主要な成果:

  • パーキンソン病は,特定の神経病理学的変化が特徴です.
  • 年齢と遺伝的要因 (例えば,LRRK-2,GBA) は,疾患の発症において極めて重要です.
  • ドーパミン置換療法と非運動症状の管理は,患者のアウトカムを改善します.

結論:

  • パーキンソン病の正確な診断は達成可能である.
  • 遺伝的感受性を理解することは,パーキンソン病の研究に不可欠です.
  • 幹細胞や遺伝子療法のような新興治療法は,将来の治療の可能性を秘めています.